Figure 4From: Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids Change from baseline in percentage of symptom-free 24-hour periods. Over Weeks 1–12, ITT population. BD: twice-daily; OD: once-daily; SAL: salmeterol; SE: standard error; VI: vilanterol.Back to article page